Zacks: Brokerages Anticipate Cara Therapeutics Inc (CARA) Will Announce Earnings of -$0.59 Per Share

Equities analysts expect Cara Therapeutics Inc (NASDAQ:CARA) to report earnings of ($0.59) per share for the current quarter, according to Zacks. Five analysts have made estimates for Cara Therapeutics’ earnings. The lowest EPS estimate is ($0.74) and the highest is ($0.49). Cara Therapeutics reported earnings of ($0.43) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 37.2%. The firm is scheduled to announce its next quarterly earnings results on Thursday, March 21st.

On average, analysts expect that Cara Therapeutics will report full year earnings of ($2.14) per share for the current year, with EPS estimates ranging from ($2.28) to ($2.02). For the next year, analysts expect that the business will post earnings of ($2.26) per share, with EPS estimates ranging from ($2.84) to ($1.82). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Cara Therapeutics.

Get Cara Therapeutics alerts:

A number of analysts have recently issued reports on the stock. Janney Montgomery Scott assumed coverage on shares of Cara Therapeutics in a report on Thursday, December 20th. They issued a “buy” rating and a $13.36 price objective on the stock. Zacks Investment Research downgraded shares of Cara Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, January 21st. HC Wainwright set a $30.00 price objective on shares of Cara Therapeutics and gave the company a “buy” rating in a report on Thursday, December 20th. Bank of America assumed coverage on shares of Cara Therapeutics in a report on Tuesday, January 15th. They issued a “neutral” rating and a $19.00 price objective on the stock. Finally, BidaskClub downgraded shares of Cara Therapeutics from a “sell” rating to a “strong sell” rating in a report on Thursday, December 13th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $24.03.

In other Cara Therapeutics news, SVP Frederique Ph.D. Menzaghi sold 4,300 shares of Cara Therapeutics stock in a transaction on Friday, December 28th. The shares were sold at an average price of $12.53, for a total transaction of $53,879.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Scott Terrillion sold 3,100 shares of Cara Therapeutics stock in a transaction on Friday, December 28th. The stock was sold at an average price of $12.51, for a total transaction of $38,781.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 95,450 shares of company stock worth $1,266,845. 6.70% of the stock is owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the business. Swiss National Bank boosted its position in Cara Therapeutics by 17.6% during the third quarter. Swiss National Bank now owns 56,100 shares of the biopharmaceutical company’s stock worth $1,344,000 after purchasing an additional 8,400 shares during the period. Virtu Financial LLC boosted its position in Cara Therapeutics by 78.5% during the fourth quarter. Virtu Financial LLC now owns 19,316 shares of the biopharmaceutical company’s stock worth $251,000 after purchasing an additional 8,496 shares during the period. Sphera Funds Management LTD. bought a new position in Cara Therapeutics during the third quarter worth $6,130,000. First Manhattan Co. boosted its position in Cara Therapeutics by 50.2% during the fourth quarter. First Manhattan Co. now owns 836,642 shares of the biopharmaceutical company’s stock worth $10,876,000 after purchasing an additional 279,642 shares during the period. Finally, Vanguard Group Inc. boosted its position in Cara Therapeutics by 24.5% during the third quarter. Vanguard Group Inc. now owns 1,551,344 shares of the biopharmaceutical company’s stock worth $37,155,000 after purchasing an additional 305,020 shares during the period. 62.66% of the stock is owned by hedge funds and other institutional investors.

NASDAQ CARA opened at $16.90 on Friday. Cara Therapeutics has a 12-month low of $11.46 and a 12-month high of $24.30. The company has a market capitalization of $669.90 million, a PE ratio of -9.09 and a beta of 2.87.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

See Also: Catch-Up Contributions

Get a free copy of the Zacks research report on Cara Therapeutics (CARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cara Therapeutics (NASDAQ:CARA)

Leave a Reply

Your email address will not be published. Required fields are marked *